Metabolic Syndrome in psoriasis: a hospital based cross-sectional study in Central India

Surendra Singh Bhati, Akhil Shah, Subhash Chaudhary, Saket Kumar, Anushtha Tomar, Shubhang Jain


Background: Psoriasis is a chronic immune-mediated inflammatory disorder, reported to be associated with obesity, dyslipidaemia and diabetes via common immunological mechanisms. All of these components ultimately increase the risk of metabolic syndrome and cardiovascular morbidities. Aims and Objectives: To assess the association of Metabolic Syndrome (MS) and its components in patients suffering from psoriasis. To study the relationship between the duration and severity of psoriasis and MS. Materials and Methods: A hospital based cross-sectional study was conducted involving 100 adult patients with psoriasis and 100 controls. All participants were evaluated forpsoriasis and the components of MS. Psoriasis was categorized as mild, moderate and severe based on Psoriasis Area and Severity Index (PASI) (<7, 8–12 and >12, respectively). In all patients and controls, body mass index was calculated, blood pressure and waist circumference were measured and fasting blood sugar and lipid profile were estimated. Results: In the present study, a higher prevalence of MS in Psoriasis patients than in controls (38% v/s 23%) was observed. Psoriatic patients had higher prevalence of hypertension (36% v/s 14%). It can be concluded that association of MS and psoriasis is independent of the type, duration and severity of psoriasis. Conclusion: The present study suggests that subjects with psoriasis present a greater risk of MS and should trigger a higher clinical suspicion for their co-existence. Psoriasis is a systemic disease with significant morbidity and mortality. This study emphasizes the critical need for providers to screen psoriasis patients for early diagnosis and treatment of associated MS. However, more number of large population based cohort studies are required to establish stronger association between psoriasis and MS.

Full Text:



Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Rook’s Textbook of Dermatology. Burns T, Breathnach S, Cox N, Griffiths C editors. Seventh edition.Blackwell Science,Oxford2005; pp. 35.1- 35.69.

Baker H. Psoriasis a review. Dermatol. 1975;150(1): 16-25.

Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999; 107(6):595-605. DOI: 10.1016/ S0002-9343(99)00284-3

BediTR.Clinical profile of psoriasis in North India. Indian J Dermatol Venereol. 1995;61(4):202-05.

Barker JNWN. The pathophysiology of psoriasis. Lancet 1993; 338(8761):227–30.doi: 1016/0140-6736(91)90357-U

Christopher E, Mrowietz U. Psoriasis. In :Freeberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s Dermatology in General Medicine : 6th Edn., Vol 1, New York : McGraw-Hill, 2003.p.407-427.

Griffiths TW, Griffiths CEM, Voorhees JJ. Immuno-pathogenesis and immunotherapy of psoriasis. Dermatol Clinics 1995;13(4):739- 749.

Reynoso-von Drateln C, Martı´nez-Abundis E, Balca´zar-Mun˜oz BR, Bustos- Saldan˜a R, Gonza´lez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003; 48 (6): 882-885.doi: 2003.446

Qureshi AA, Choi HK, Setty AR, CurhanGC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145 (4): 379-382.doi: 10.1001/archdermatol. 2009.48

Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-8. Epub 2006. doi:10.1007/s00403-006-0703-z

Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardio-vascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35. Epub2006. doi: 10. 1016/j. jaad.2006.08.040

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003; 107(3): 391-7. doi:10.1161/01.cir. 0000055014. 62083.05

Gennuso KP, Gangnon RE, Thraen-Borowski KM, Colbert LH. Dose-response relationships between sedentary behaviour and the metabolic syndrome and its components. Diabetologia. 2015;58(3):485-92. doi: 10.1007 /s00125-014-3453-z. Epub 2014.

Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006;155(6):1165-9. doi:10.1111/j. 1365-2133.2006.07503.x

Naldi L, Chatenoud L, Linder D, BelloniFortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61-7.doi:10.1111/j. 0022-202X.2005.23681.x

Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203-9. Epub 2006. doi:10. 1016/j. semarthrit.2006.09.001

National Institute of Health. Third report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH publ. no. 01-3670. Bethesda, MD: National Institute of Health, National Heart, Lung and Blood Institute, 2001.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. doi:10.1002/(SICI)1096-9136 (199807)15:7<539::AID-DIA668>3.0.CO;2-S

Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. CurrRheumatol Rep. 2006;8(5):355-63.

Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007; 157(1):68-73. Epub 2007 Jun 6. doi:10.1111/j.1365-2133.2007. 07986.x

Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci. 2010; 57(2):143-4. doi: 10.1016/j.jdermsci.2009. 11.002. Epub2009 .

Madanagobalane S, AnandanS. Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome :A hospital based case control study. Indian J Dermatol 2012;57(5):353-357. doi: 10.4103/0019-5154.100474

Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol VenereolLeprol. 2010;76(6):662-5. doi: 10.4103/0378-6323.72462.

Khunger N, Gupta D, Ramesh V. Is psoriasis a new cutaneous marker for metabolic syndrome? A study in Indian patients. Indian J Dermatol. 2013;58(4):313. doi: 10.4103/0019-5154.113958

Prathap P, Asokan N, Manjula VD. A case control study to determine the association of psoriasis with metabolic syndrome in a tertiary care centre. Age (Mean±standard deviation (SD). 2014; 48 (12.83):51-4.

Zindancı I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, Koç M. Prevalence of metabolic syndrome in patients with psoriasis. Scientific World J. 2012;2012. doi:10.1100/2012/312463

Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-6. doi: 10.1093/eurheartj/ ehp567. Epub 2009 Dec 27.

Ghiasi M, Nouri M, Abbasi A, Hatami P, Abbasi MA, Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian journal of dermatology. 2011;56(5):533. doi: 10.4103/0019-5154. 87149.

Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012; 148(9): 995-1000. doi: 10.1001/ archdermatol. 2012.1401.

Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22): 2644-50. DOI:10.1001/archinte.165.22.2644

Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906-12. Epub 2006.doi:

Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33(2):351-75. DOI:10.1016/j.ecl.2004.03.005

Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005; 365(9468): 1398-405. DOI:10. 1016/ S0140-6736(05)66375-1

Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199-205.

Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005; 11(5): RA155-162. Epub 2005.

Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012 Mar;132(3 Pt 1):556-62.doi:10.1038/jid.2011.365. Epub 2011.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis.JAMA. 2006; 296 (14): 1735-41. DOI:10.1001/jama.296.14.1735.


  • There are currently no refbacks.